Starpharma and Peter Mac Cancer Centre awarded DEP® Grant
Starpharma (ASX: SPL, OTCQX: SPHRY) and Peter MacCallum Cancer Centre (Peter Mac) have been awarded a further Federal Government Innovation Connections grant to support innovative research within Starpharma’s DEP® oncology program. Starpharma’s proprietary DEP® dendrimer platform improves efficacy…
LBT Receives $4.2 Million in R&D Incentives
Australian medical technology company LBT Innovations Limited (ASX:LBT) has received an R&D Incentive, net of income tax payable, of $3.98 Million for the financial year ended 30 June 2017. In addition, LBT has also received $0.22 Million for…
AdAlta appoints Dr Dallas Hartman as Chief Operating Officer
AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the appointment of experienced executive, Dr Dallas Hartman to the role of Chief Operating Officer. Dr Hartman will bring…
BioMelbourne Network submission to the Policy Consultation Paper – Visa Simplification: Transforming Australia’s Visa System
October 2017 “Australia’s visa system must remain globally competitive to attract talent to build future industries and transition to a knowledge-led economy” Health is a global market and access to global talent is critical for healthcare innovation. Companies…
GKC names John Schellhorn new President and CEO
GKC announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company’s Board of Directors. Schellhorn joins GKC with a proven track record to spearhead the company’s accelerated…
Victoria’s new Boston office to help connect our world class med tech & pharma sector to key North American markets
The Andrews Labor Government today further expanded its international trade network with the opening of a new trade office in Boston. Minister for Small Business, Innovation and Trade Philp Dalidakis formally opened the new Victorian Government Trade and…
St Vincent’s Hospital Commences Global First APAS® In Situ Automated Evaluation
Australian developed advanced pathology instrument reading and interpreting plates for faster diagnosis of infectious diseases Centre of excellence laboratory to test automation efficiency in a busy real-life setting Adelaide, Australia, 27 September 2017: Australian medical technology…
U.S. Patent Granted for Cynata Cymerus™ Technology
Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering aspects of Cynata’s proprietary Cymerus™ mesenchymal stem cell technology.…
Penthrox is recommended for use in all UK ambulances
Medical Developments International Ltd (ASX: MVP) is delighted to advise the Joint Royal Colleges Ambulance Liaison Committee (JRCALC) has issued its new pain management clinical practice guidelines for UK ambulance services teams. The JRCALC guidelines now recommend the…
Sienna Diagnostics: Exclusive Distributor Appointed for Denmark and Sweden
Melbourne, Australia, 25 September 2017: Sienna Cancer Diagnostics, a commercial stage, medical technology company focussed on the development and commercialisation of innovative cancer-related tests, is pleased to announce the appointment of Axlab A/S as its exclusive distribution partner…
Starpharma – DEP® docetaxel positive phase 1 results; phase 2 commences
DEP® docetaxel phase 1 trial successfully completed with phase 2 to commence immediately DEP® docetaxel patients had no reports of neutropenia, a life-threatening toxicity seen in virtually all patients treated with conventional docetaxel formulations (e.g. Taxotere®) Encouraging signs of efficacy observed…
5th October – BioWorkshop – Global Pathways to Pre-Clinical Development Success
Learn approaches on how to design your pre-clinical studies from the experts! This workshop will cover global technical and regulatory strategies for pre-clinical development of medicines, from small molecules and biologics, to cell and gene therapies. Attendees will…
